26126965|t|Humoral factors in ALS patients during disease progression.
26126965|a|BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting upper and lower motor neurons in the CNS and leading to paralysis and death. There are currently no effective treatments for ALS due to the complexity and heterogeneity of factors involved in motor neuron degeneration. A complex of interrelated effectors have been identified in ALS, yet systemic factors indicating and/or reflecting pathological disease developments are uncertain. The purpose of the study was to identify humoral effectors as potential biomarkers during disease progression. METHODS: Thirteen clinically definite ALS patients and seven non-neurological controls enrolled in the study. Peripheral blood samples were obtained from each ALS patient and control at two visits separated by 6 months. The Revised ALS Functional Rating Scale (ALSFRS-R) was used to evaluate overall ALS-patient functional status at each visit. Eleven humoral factors were analyzed in sera. Cytokine levels (GM-CSF, IL-1beta, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, and TNF-alpha) were determined using the Bio-Rad Bio-Plex  Luminex 200 multiplex assay system. Nitrite, a breakdown product of NO, was quantified using a Griess Reagent System. Glutathione (GSH) concentrations were measured using a Glutathione Fluorometric Assay Kit. RESULTS: ALS patients had ALSFRS-R scores of 30.5 +- 1.9 on their first visit and 27.3 +- 2.7 on the second visit, indicating slight disease progression. Serum multiplex cytokine panels revealed statistically significant changes in IL-2, IL-5, IL-6, and IL-8 levels in ALS patients depending on disease status at each visit. Nitrite serum levels trended upwards in ALS patients while serum GSH concentrations were drastically decreased in sera from ALS patients versus controls at both visits. CONCLUSIONS: Our results demonstrated a systemic pro-inflammatory state and impaired antioxidant system in ALS patients during disease progression. Increased levels of pro-inflammatory IL-6, IL-8, and nitrite and significantly decreased endogenous antioxidant GSH levels could identify these humoral constituents as systemic biomarkers for ALS. However, systemic changes in IL-2, IL-5, and IL-6 levels determined between visits in ALS patients might indicate adaptive immune system responses dependent on current disease stage. These novel findings, showing dynamic changes in humoral effectors during disease progression, could be important for development of an effective treatment for ALS.
26126965	19	22	ALS	Disease	MESH:D000690
26126965	23	31	patients	Species	9606
26126965	72	101	Amyotrophic lateral sclerosis	Disease	MESH:D000690
26126965	103	106	ALS	Disease	MESH:D000690
26126965	113	138	neurodegenerative disease	Disease	MESH:D019636
26126965	205	214	paralysis	Disease	MESH:D010243
26126965	274	277	ALS	Disease	MESH:D000690
26126965	341	366	motor neuron degeneration	Disease	MESH:D009410
26126965	428	431	ALS	Disease	MESH:D000690
26126965	681	684	ALS	Disease	MESH:D000690
26126965	685	693	patients	Species	9606
26126965	802	805	ALS	Disease	MESH:D000690
26126965	806	813	patient	Species	9606
26126965	875	878	ALS	Disease	MESH:D000690
26126965	943	946	ALS	Disease	MESH:D000690
26126965	947	954	patient	Species	9606
26126965	1051	1057	GM-CSF	Gene	1437
26126965	1059	1067	IL-1beta	Gene	3553
26126965	1069	1073	IL-2	Gene	3558
26126965	1075	1079	IL-4	Gene	3565
26126965	1081	1085	IL-5	Gene	3567
26126965	1087	1091	IL-6	Gene	3569
26126965	1093	1097	IL-8	Gene	3576
26126965	1099	1104	IL-10	Gene	3586
26126965	1110	1119	TNF-alpha	Gene	7124
26126965	1201	1208	Nitrite	Chemical	MESH:D009573
26126965	1283	1294	Glutathione	Chemical	MESH:D005978
26126965	1296	1299	GSH	Chemical	MESH:D005978
26126965	1338	1349	Glutathione	Chemical	MESH:D005978
26126965	1383	1386	ALS	Disease	MESH:D000690
26126965	1387	1395	patients	Species	9606
26126965	1606	1610	IL-2	Gene	3558
26126965	1612	1616	IL-5	Gene	3567
26126965	1618	1622	IL-6	Gene	3569
26126965	1628	1632	IL-8	Gene	3576
26126965	1643	1646	ALS	Disease	MESH:D000690
26126965	1647	1655	patients	Species	9606
26126965	1699	1706	Nitrite	Chemical	MESH:D009573
26126965	1739	1742	ALS	Disease	MESH:D000690
26126965	1743	1751	patients	Species	9606
26126965	1764	1767	GSH	Chemical	MESH:D005978
26126965	1823	1826	ALS	Disease	MESH:D000690
26126965	1827	1835	patients	Species	9606
26126965	1921	1933	inflammatory	Disease	MESH:D007249
26126965	1975	1978	ALS	Disease	MESH:D000690
26126965	1979	1987	patients	Species	9606
26126965	2040	2052	inflammatory	Disease	MESH:D007249
26126965	2053	2057	IL-6	Gene	3569
26126965	2059	2063	IL-8	Gene	3576
26126965	2069	2076	nitrite	Chemical	MESH:D009573
26126965	2128	2131	GSH	Chemical	MESH:D005978
26126965	2208	2211	ALS	Disease	MESH:D000690
26126965	2242	2246	IL-2	Gene	3558
26126965	2248	2252	IL-5	Gene	3567
26126965	2258	2262	IL-6	Gene	3569
26126965	2299	2302	ALS	Disease	MESH:D000690
26126965	2303	2311	patients	Species	9606
26126965	2556	2559	ALS	Disease	MESH:D000690
26126965	Positive_Correlation	MESH:D009573	MESH:D007249
26126965	Association	MESH:D000690	3586
26126965	Association	MESH:D000690	3558
26126965	Association	MESH:D000690	7124
26126965	Association	MESH:D000690	3565
26126965	Positive_Correlation	MESH:D007249	3569
26126965	Association	MESH:D000690	3576
26126965	Association	MESH:D007249	3576
26126965	Association	MESH:D000690	3569
26126965	Association	MESH:D000690	3567
26126965	Negative_Correlation	MESH:D005978	MESH:D007249

